Home
/
Resources
/
Webinars
/
AI and Emerging Technologies in Clinical Trials: Practical A...
Webinars
AI and Emerging Technologies in Clinical Trials: Practical Applications and Regulatory Considerations
Clinical trials are undergoing a fundamental shift as emerging technologies reshape how studies are designed, executed, and evaluated. For biopharma companies, the pressure to accelerate timelines, improve efficiency, and reduce risk has made the integration of these technologies increasingly critical.
This webinar will explore how artificial intelligence (AI) and other key technology-enabled approaches are being applied across clinical trials today. From protocol development and feasibility assessment to patient identification, trial execution, and data analysis, AI is enabling more informed decision-making earlier in the development process. At the same time, decentralized and hybrid trial models are changing how studies are conducted, expanding patient access and enabling more flexible, real-world data collection.
Alongside these advances, modeling and simulation continues to play a central role in clinical development. As an established approach accepted by regulatory authorities, modeling and simulation supports dose selection, study design, and risk reduction, and remains a critical component of data-driven decision making.
Importantly, the application of these technologies must align with evolving regulatory expectations. Considerations such as data quality, transparency, patient representativeness and validation of novel approaches are increasingly central to regulatory review.
This session will provide a practical, integrated view of how AI, decentralized trial technologies, and modeling and simulation are being used in clinical trials today, and what biopharma companies should consider when applying these approaches in a regulatory context.
What You Will Learn
How AI is being applied across protocol development, patient recruitment and trial operations
The role of decentralized and hybrid trial approaches in improving execution and patient access
How modeling and simulation support study design and regulatory decision making
Key regulatory considerations when applying emerging technologies in clinical trials
Speakers
Nate Thompson, Chief Information Officer, Allucent
With over 20 years of leadership experience in life sciences technology, Nate Thompson brings a deep expertise in optimizing digital operations and enabling data-driven decision-making across the drug development lifecycle. Nate has a distinguished track record of leading enterprise-wide transformations, with core strengths in AI integration, real-time data platforms, scalable enterprise architecture and M&A technology alignment. Prior to joining Allucent, he served as Chief Technology & Information Officer at United BioSource (UBC), where he led global technology teams and delivered substantial operational efficiencies. His career spans key technology leadership roles at CROs, including Premier Research and Syneos Health, where he pioneered enterprise architecture strategies and drove innovation in clinical technology platforms.
Nate is passionate about leveraging technology to create meaningful outcomes for both customers and patients.
Sugato De, Senior Vice President, Product Development Consulting, Allucent
As a former Senior Policy Advisor at the FDA and a seasoned leader within the CRO industry, Sugato De has cultivated expertise in a plethora of regulatory pathways, including dossiers for combination products, expedited pathways, protocol development for medical devices and more. During his 11-year tenure with the Center for Devices and Radiological Health (CDRH) at the US FDA, Sugato developed specialized expertise in drug-device combination products, digital health technologies and critical care medicine.
Martin Johnson, PhD, Executive Director, Pharmacometrics, Allucent
Dr. Martin Johnson has over 20 years of experience in pharmacokinetics and pharmacometrics, gained through roles at Merck Sharp & Dohme (MSD-NL/UK), AstraZeneca (UK), and Orchid Research Labs (India). His career has focused on applying quantitative methods to support drug development, particularly in oncology and neuroscience. As Executive Director of Pharmacometrics at Allucent, Dr. Johnson develops and implements pharmacometrics models to inform critical decisions across various stages of drug development. He collaborates with cross-functional teams to optimize dosing strategies, predict clinical outcomes, and contribute to regulatory submissions, leading to the approval of several significant medicines.
Christine Khoza, Executive Director, Global Head, SSU & Site Intelligence, Allucent
Christine Khoza has more than 23 years’ professional experience in clinical research. As Executive Director and Global Head of Study Start-Up & Site Intelligence at Allucent, she ensures planning, preparation and execution of study start-up activities, from site identification to site activation. With a strong foundation in data-driven decision-making, Christine combines scientific rigor, strategic leadership, and operational expertise to enhance clinical trial efficiency and outcomes. Her career reflects a consistent track record of leading high-performing teams, streamlining global processes, and delivering scalable solutions in highly regulated environments.
By submitting your information to us via the Allucent website, your business details will be securely added to our database. For information on our privacy practices, please review our
Privacy Policy
